论文部分内容阅读
目的探讨口服不同剂量红霉素对早产儿喂养不耐受的治疗效果及可能存在的不良反应。方法选取2008年1月至2010年3月在广东省16家三级甲等医院新生儿科住院并诊断为喂养不耐受的早产儿,随机分为3组:大剂量组(第8～10日龄起口服红霉素12.5mg/kg,每8h给药,疗程7～10天),小剂量组(口服红霉素5mg/kg,给药方法同上),对照组(完全不用胃肠动力调节药物)。记录临床资料,比较各组患儿的喂养相关指标及宫外生长迟缓(EUGR)发生率等,并评估药物不良反应。结果纳入研究的患儿共122例,其中大剂量组37例,小剂量组47例,对照组38例。入组后两治疗组患儿体重增长速度、体重开始增长日龄、肠内热卡达到基础热卡日龄、达到全肠道喂养日龄及体重EUGR发生率等方面均较对照组明显改善(P<0.05),但按胎龄32周再分亚组后比较,以体重为指标EUGR发生率差异无统计学意义(P>0.05)。所有治疗组患儿随访6个月均未见明显红霉素不良反应。结论本研究中选取的两种剂量红霉素口服对早产儿(包括胎龄<32周者)喂养不耐受均有治疗作用,所采用的红霉素治疗方案未见明显不良反应。
Objective To investigate the therapeutic effect and possible adverse reactions of oral administration of different doses of erythromycin on preterm infants intolerant. Methods From January 2008 to March 2010, 16 preterm infants admitted to Neonatology Department of Grade-A hospitals in Guangdong Province were diagnosed as feeding intolerance, and were randomly divided into three groups: high-dose group (days 8-10 Erythromycin 12.5mg / kg from the age of oral administration, administered every 8h, the course of treatment 7 to 10 days), low-dose group (oral erythromycin 5mg / kg, method of administration as above), the control group drug). The clinical data were recorded. The feeding-related indicators and the incidence of extrauterine growth retardation (EUGR) in each group were compared, and adverse drug reactions were evaluated. Results A total of 122 children were included in the study, including 37 cases in the high-dose group, 47 cases in the low-dose group and 38 cases in the control group. Compared with the control group, the body weight gain rate, body weight gaining age, enteral heat card reaching the basic fever card age, total gut feeding day and the weight of EUGR were significantly improved in the two treatment groups (P <0.05). However, there was no significant difference in the incidence of EUGR based on body weight (P> 0.05). All treatment groups were followed up for 6 months showed no obvious erythromycin adverse reactions. Conclusion The two doses of erythromycin selected in this study have therapeutic effect on the feeding intolerance in premature infants (including gestational age less than 32 weeks), and the treatment with erythromycin has no obvious adverse reactions.